Skip to main content

Acer Therapeutics Inc. (ACER)

NASDAQ: ACER · Delayed Price · USD
2.52 0.06 (2.44%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap35.92M
Revenue (ttm)4.00M
Net Income (ttm)-16.91M
Shares Out14.31M
EPS (ttm)-1.29
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,166
Open2.43
Previous Close2.46
Day's Range2.41 - 2.55
52-Week Range2.28 - 5.39
Beta1.17
AnalystsBuy
Price Target10.00 (+296.8%)
Est. Earnings DateNov 10, 2021

About ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatme...

IndustryPharmaceuticals
Founded2013
CEOChristopher Schelling
Employees23
Stock ExchangeNASDAQ
Ticker SymbolACER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ACER stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 296.83% from the latest price.

Price Target
$10.00
(296.83% upside)
Analyst Consensus: Buy

News

Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

3 weeks ago - GlobeNewsWire

Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

1 month ago - GlobeNewsWire

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 ...

NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of ther...

1 month ago - GlobeNewsWire

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

Other symbols:CPIXORGOXNCR
2 months ago - Zacks Investment Research

Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled

3 months ago - GlobeNewsWire

What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercializat...

3 months ago - GlobeNewsWire

Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update

NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rar...

4 months ago - GlobeNewsWire

Acer Therapeutics to Participate in Needham Virtual Healthcare Conference

NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

5 months ago - GlobeNewsWire

Notice of Settlement of Derivative Suits

NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

5 months ago - GlobeNewsWire

Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics

Relief Therapeutics Holding AG (OTCMKTS: RLFTF) and Acer Therapeutics Inc (NASDAQ: ACER) have entered into a Collaboration and License Agreement for worldwide development and commercialization of ACER-0...

5 months ago - Benzinga

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization...

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights

5 months ago - GlobeNewsWire

ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher

Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics. The post ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing High...

6 months ago - InvestorPlace

What's Happening With ACER Stock, MGM Stock, XPEV Stock?

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Other symbols:MGMXPEV
6 months ago - Benzinga

Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious r...

6 months ago - GlobeNewsWire

Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed...

Targeting a pre-NDA meeting with FDA in Q2 2021 Targeting a pre-NDA meeting with FDA in Q2 2021

7 months ago - GlobeNewsWire

Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and Lice...

Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief

7 months ago - GlobeNewsWire

Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders

Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

8 months ago - GlobeNewsWire

Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

10 months ago - GlobeNewsWire

ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics ...

LOS ANGELES--(BUSINESS WIRE)---- $ACER #ACER--ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc.

11 months ago - Business Wire

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

NEWTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ra...

11 months ago - GlobeNewsWire

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious ...

1 year ago - GlobeNewsWire

Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders

1 year ago - GlobeNewsWire

Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives ...

SAN DIEGO & NEWTON, Mass.--(BUSINESS WIRE)---- $ACER #ClassAction--Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc.

1 year ago - Business Wire